McKesson Corporation’s Stock Price Plummets to $547.51, Sliding by a Significant 11.34%

McKesson Corporation (MCK)

547.51 USD -70.00 (-11.34%) Volume: 4.07M

McKesson Corporation’s stock price is currently at 547.51 USD, experiencing a notable decline of -11.34% this trading session with a trading volume of 4.07M. Despite the recent dip, MCK’s year-to-date performance remains strong with an increase of +18.26%, affirming its robust market presence.

Latest developments on McKesson Corporation

McKesson Corp has been experiencing fluctuations in its stock price recently, with mixed outcomes in the market. Despite a rise in stock on Tuesday, the company still underperforms compared to the overall market. The fiscal Q1 earnings snapshot showed a revenue shortfall in the U.S. pharmaceutical segment, leading to a miss in quarterly revenue. However, the company’s Q1 2025 earnings call highlighted strong revenue growth and increased guidance, which was well-received by investors. Mizuho even raised McKesson’s stock target, showing confidence in the company’s future performance. Additionally, McKesson announced plans to buy back $4 billion in company shares, indicating a strategic move to boost shareholder value. Overall, while facing challenges in certain segments, McKesson remains focused on growth and profitability.

McKesson Corporation on Smartkarma

Analysts at Baptista Research on Smartkarma have provided positive coverage of Mckesson Corp, a diversified health care services company. In their research report titled “McKesson Corporation: How Is The Revenue and Profit Growth Across Segments Expected To Evolve? – Major Drivers,” they highlighted the company’s strong financial performance in the Fourth Quarter Fiscal 2024. With consolidated revenue increasing by 12% to $309 billion and adjusted earnings per diluted share rising by 6% to $27.44, Mckesson Corp exceeded expectations set at the start of the fiscal year. The analysts attributed this growth to the company’s differentiated portfolio of assets, innovative solutions, and commitment to quality and operational excellence.

In another report by Baptista Research on Smartkarma, titled “McKesson Corporation: Anticipated Revenue Growth in Medical-Surgical Solutions Could Propel Them Forward! – Major Drivers,” analysts continued to express bullish sentiment towards Mckesson Corp. The company’s robust fiscal third-quarter earnings, with total revenues of $80.9 billion and adjusted earnings per diluted share of $7.74, showcased double-digit growth year over year. The analysts noted that this strong financial performance was a result of Mckesson Corp‘s focused execution against their long-term priorities in the health care services sector.

A look at McKesson Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

McKesson Corp’s long-term outlook seems promising based on the Smartkarma Smart Scores. With high scores in Growth, Resilience, and Momentum, the company appears to be well-positioned for future success. Its focus on developing software for the health industry and offering various solutions for payers indicates a strong potential for continued growth and innovation in the healthcare sector.

Although McKesson Corp’s Value score is lower, the combination of solid scores in Dividend, Growth, Resilience, and Momentum suggests a positive overall outlook for the company. With a strong presence in distributing pharmaceuticals and healthcare products in North America, coupled with its software development and data integration services, McKesson Corp is likely to remain a key player in the healthcare industry for the foreseeable future.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma